牛牛AI助理已提取核心訊息
RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced on January 25, 2024, that the U.S. Patent and Trademark Office (USPTO) has granted a new patent for Talicia, their treatment for Helicobacter pylori (H. pylori) infection. The patent, U.S. Patent No. 11,878,011, covers the use of Talicia as a method for eradicating H. pylori regardless of patient Body Mass Index (BMI) and extends its protection until May 2042. This development is significant as obesity rates in the U.S. continue to climb, and obesity has been linked to the failure of other H. pylori treatments. Talicia, which is a combination of two antibiotics and a proton pump inhibitor, is the leading branded first-line therapy for H. pylori prescribed by U.S. gastroenterologists. The drug is also eligible for eight years of U.S. market exclusivity under its Qualified Infectious Disease Product designation and is protected by additional patents extending until 2034, with further patents pending worldwide.
RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced on January 25, 2024, that the U.S. Patent and Trademark Office (USPTO) has granted a new patent for Talicia, their treatment for Helicobacter pylori (H. pylori) infection. The patent, U.S. Patent No. 11,878,011, covers the use of Talicia as a method for eradicating H. pylori regardless of patient Body Mass Index (BMI) and extends its protection until May 2042. This development is significant as obesity rates in the U.S. continue to climb, and obesity has been linked to the failure of other H. pylori treatments. Talicia, which is a combination of two antibiotics and a proton pump inhibitor, is the leading branded first-line therapy for H. pylori prescribed by U.S. gastroenterologists. The drug is also eligible for eight years of U.S. market exclusivity under its Qualified Infectious Disease Product designation and is protected by additional patents extending until 2034, with further patents pending worldwide.
專業生物製藥公司RedHill Biopharma Ltd. 於2024年1月25日宣佈，美國專利商標局（USPTO）已爲其治療幽門螺桿菌（H. pylori）感染的塔利西亞授予了一項新專利。該專利，美國專利號爲11,878,011，涵蓋了使用塔利西亞作爲根除幽門螺桿菌的方法，無論患者體重指數（BMI）如何，並將其保護期延長至2042年5月。隨着美國肥胖率的持續攀升，這一發展意義重大，肥胖與其他幽門螺桿菌治療的失敗有關。塔利西亞結合了兩種抗生素和一種質子泵抑制劑，是美國胃腸病學家開的領先品牌幽門螺桿菌一線療法。該藥物憑藉其合格傳染病產品稱號，還有資格在美國市場獨家經營八年，並受延期至2034年的其他專利保護，全球還有更多專利正在申請中。
專業生物製藥公司RedHill Biopharma Ltd. 於2024年1月25日宣佈，美國專利商標局（USPTO）已爲其治療幽門螺桿菌（H. pylori）感染的塔利西亞授予了一項新專利。該專利，美國專利號爲11,878,011，涵蓋了使用塔利西亞作爲根除幽門螺桿菌的方法，無論患者體重指數（BMI）如何，並將其保護期延長至2042年5月。隨着美國肥胖率的持續攀升，這一發展意義重大，肥胖與其他幽門螺桿菌治療的失敗有關。塔利西亞結合了兩種抗生素和一種質子泵抑制劑，是美國胃腸病學家開的領先品牌幽門螺桿菌一線療法。該藥物憑藉其合格傳染病產品稱號，還有資格在美國市場獨家經營八年，並受延期至2034年的其他專利保護，全球還有更多專利正在申請中。
有用
沒用